CARISMA Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 – Friday, May 14 .
| PHILADELPHIA, April 28, 2021 /PRNewswire/ -- Carisma Therapeutics Inc. a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 – Friday, May 14. The findings mark the first time chimeric antigen receptor macrophages (CAR-Ms) have been assessed in a fully immunocompetent animal model and highlight the potential of CAR-monocytes (CAR-Mono) as an innovative and expedited immunotherapeutic pathway.
Dr. Stefano Pierini, Senior Scientist at CARISMA, will present findings from “Chimeric Antigen Receptor Macrophages (CAR-M) Induce Anti-Tumor Immunity and Synergize with Immune Checkpoint Inhibitors in Pre-Clinical Solid Tumor Models,” which established a fully immunocompetent solid tumor mouse model and evaluated the interaction of CAR-M with the tumor microenvironment and the endogenous adaptive immune system. The findings demonstrate that CAR-M therapy showed significant tumor control, increased overall survival, remodeled tumor microenvironment, and protected mice from antigen negative tumor recurrence. The results also exhibit that CAR-M synergize with T cell checkpoint inhibitors against PD1 resistant solid tumors. The data complement findings from CARISMA’s foundational CAR-M platform that were published in Nature Biotechnology in March 2020. CARISMA Scientist, Dr. Linara Gabitova, will present “Anti-HER2 CAR Monocytes Demonstrate Targeted Anti-Tumor Activity and Enable a Single Day Cell Manufacturing Process,” which shows the successful development of CAR-Mono with direct anti-tumor activity and capacity to differentiate into M1-polarized CAR-M. In this study, CARISMA also established an ultra-rapid, same-day CAR-Mono manufacturing process, which holds the potential to significantly reduce the future cost of goods and manufacturing turn-around-time associated with the autologous cell therapy. The following presentations will be available on the ASGCT Annual Meeting website for registered attendees during the dates/times indicated below:
About CARISMA Therapeutics Inc. For more information, please visit www.carismatx.com Media Contact:
SOURCE Carisma Therapeutics Inc. |
View original content to download multimedia:
